Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$32.68 USD
+0.11 (0.34%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $32.70 +0.02 (0.06%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VKTX 32.68 +0.11(0.34%)
Will VKTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VKTX
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Other News for VKTX
Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets
Viking Therapeutics Q2: Confidently Continuing The Recovery
Viking Therapeutics Receives Buy Rating Amid Promising Clinical Developments and Strategic Initiatives